List of Excipients in Branded Drug MULTAQ

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Sanofi-Aventis US LLC	MULTAQ	dronedarone	0024-4142	CARNAUBA WAX	2029-04-16
Sanofi-Aventis US LLC	MULTAQ	dronedarone	0024-4142	CROSPOVIDONE	2029-04-16
Sanofi-Aventis US LLC	MULTAQ	dronedarone	0024-4142	HYPROMELLOSE	2029-04-16
Sanofi-Aventis US LLC	MULTAQ	dronedarone	0024-4142	LACTOSE MONOHYDRATE	2029-04-16
Sanofi-Aventis US LLC	MULTAQ	dronedarone	0024-4142	MAGNESIUM STEARATE	2029-04-16
Sanofi-Aventis US LLC	MULTAQ	dronedarone	0024-4142	POLOXAMER 407	2029-04-16
Sanofi-Aventis US LLC	MULTAQ	dronedarone	0024-4142	POLYETHYLENE GLYCOL 6000	2029-04-16

Multaq Excipient Strategy and Commercial Opportunities for Dronedarone

Last updated: August 22, 2026

Multaq, Sanofi's dronedarone product, uses a conventional immediate-release film-coated tablet containing lactose, hypromellose, poloxamer 407, crospovidone, colloidal anhydrous silica, and magnesium stearate. The formulation strategy addresses manufacturability and oral delivery, but dronedarone's low aqueous solubility and food-dependent exposure create opportunities for differentiated excipient systems, generic formulation development, lifecycle management, and contract manufacturing.

What is Multaq and how is it formulated?

Multaq contains dronedarone hydrochloride, an antiarrhythmic indicated in the United States to reduce the risk of hospitalization for atrial fibrillation in patients in sinus rhythm with a history of paroxysmal or persistent atrial fibrillation. The recommended dose is 400 mg twice daily with the morning and evening meals [1].

The marketed product is a 400 mg immediate-release, film-coated tablet. The FDA label identifies the following inactive ingredients [1]:

Formulation component	Listed excipient or material	Likely technical role
Tablet core	Lactose monohydrate	Diluent and tablet-mass builder
Tablet core	Hypromellose	Binder and matrix-forming aid
Tablet core	Poloxamer 407	Wetting and solubilization aid
Tablet core	Crospovidone	Superdisintegrant
Tablet core	Colloidal anhydrous silica	Glidant and moisture-flow control
Tablet core	Magnesium stearate	Lubricant
Film coat	Hypromellose	Film-forming polymer
Film coat	Macrogol 6000	Plasticizer and coating-processing aid
Film coat	Titanium dioxide	Opacifier and colorant
Film coat	Carnauba wax	Surface-finishing agent

The formulation combines a standard direct-compression or wet-granulation excipient platform with poloxamer 407, which can improve wetting of a poorly water-soluble active pharmaceutical ingredient. Crospovidone supports rapid tablet breakup, while hypromellose contributes binding and mechanical strength.

What excipient problem does dronedarone create?

Dronedarone hydrochloride has limited aqueous solubility. Oral exposure is materially affected by food, and the prescribing information requires administration with a meal [1]. A formulation developer therefore has to manage three commercial requirements:

1. Provide consistent dissolution from a high-dose tablet.
2. Maintain exposure within the established food-effect and dosing framework.
3. Preserve tablet robustness while limiting tablet size and manufacturing complexity.

The current Multaq formulation does not appear to use a sophisticated lipid formulation, amorphous solid dispersion, nanocrystal platform, or modified-release system. Its commercial value comes from a relatively simple solid oral dosage form that uses a surfactant-like excipient, disintegrant, and conventional processing aids.

That simplicity creates both opportunity and risk. A generic developer may be able to reproduce the dosage form with widely available excipients. A lifecycle developer, by contrast, may seek to improve fed-state consistency, reduce food dependence, lower pill burden, or create a more flexible dosage form.

What excipient strategy does Multaq use?

Poloxamer 407 for wetting and solubilization

Poloxamer 407 is the most strategically significant excipient in the Multaq tablet. It is a nonionic block copolymer used in oral formulations as a wetting agent, solubilizer, and processing aid. Its presence indicates that interfacial wetting and dissolution performance were important formulation considerations.

For a poorly soluble active, poloxamer can improve contact between the drug and gastrointestinal fluid. The commercial tradeoff is that surfactant concentration, solid-state behavior, and manufacturing conditions can affect dissolution stability over time.

Potential development issues include:

• Excipient distribution within the granule or blend.
• Segregation during compression.
• Impact on tablet hardness and disintegration.
• Interaction with packaging moisture.
• Batch-to-batch dissolution variability.
• Compatibility with alternate manufacturing processes.

A generic formulation that substitutes sodium lauryl sulfate, another poloxamer grade, a nonionic surfactant, or a polymeric solubilizer may require comparative dissolution and bioequivalence support. A substitution is not automatically interchangeable from a regulatory perspective.

Crospovidone for rapid disintegration

Crospovidone is a crosslinked polyvinylpyrrolidone used as a superdisintegrant. In Multaq, it supports breakup of the compressed tablet after administration. Its performance depends on particle size, grade, concentration, compression force, and the distribution of the excipient within the tablet.

Crospovidone is commercially attractive because several suppliers offer pharmacopeial grades. A developer can optimize:

• Intragr intragranular versus extragranular placement.
• Total concentration.
• Compression force.
• Tablet porosity.
• Disintegration time.
• Dissolution profile after storage.

The risk is that aggressive compression optimization can produce a mechanically strong tablet with slower drug release. Conversely, excessive disintegrant or low compression force can increase friability and packaging losses.

Lactose monohydrate as a low-cost diluent

Lactose monohydrate provides bulk and improves tablet manufacturability. It is a mature, globally available excipient with a broad supplier base. It also introduces common formulation controls:

• Lactose grade and particle-size distribution.
• Moisture content.
• Reducing-sugar compatibility.
• Patient sensitivity considerations.
• Regional availability and supplier qualification.

For a generic product, lactose offers a low-cost path to a Multaq-like formulation. A lactose-free product could use microcrystalline cellulose, mannitol, dibasic calcium phosphate, or a spray-dried composite excipient. Such substitution could support a differentiated product claim, but it may alter tablet density, dissolution, and bioequivalence performance.

Hypromellose for binding and coating

Hypromellose appears in both the tablet core and film coat. In the core, it can improve powder binding and tablet integrity. In the coating, it forms the primary protective film.

The use of the same excipient family in separate manufacturing stages simplifies procurement but does not eliminate grade-selection requirements. Core-grade hypromellose and coating-grade hypromellose may differ in viscosity, particle size, and processing behavior.

A reformulation developer could examine:

• Lower-viscosity hypromellose.
• Polyvinyl alcohol-based film coating.
• Immediate-release coating systems.
• Opacifier-free or reduced-titanium-dioxide coating.
• Pigment changes for product differentiation.
• Moisture-barrier coatings for stability improvement.

A coating change is commercially useful when it improves tablet identification, reduces coating time, supports regional color requirements, or reduces reliance on a constrained excipient.

What formulation opportunities exist for Multaq?

Generic immediate-release tablets

The largest near-term opportunity is an AB-rated generic tablet that matches the 400 mg strength and immediate-release profile. The formulation barrier is moderate rather than extreme. The developer must replicate the critical quality attributes of the reference product, including:

• Assay and content uniformity.
• Tablet hardness and friability.
• Disintegration.
• Dissolution across relevant pH conditions.
• Impurity profile.
• Stability.
• Bioequivalence under fed and fasted conditions where required.

The most efficient strategy is usually an excipient platform close to the reference formulation. Major departures increase development cost and bioequivalence risk.

Lactose-free or excipient-reduced products

A lactose-free dronedarone tablet could target patients or prescribers seeking an alternative inactive-ingredient profile. The market is likely narrower than the conventional generic market, but the product could have value in institutional formularies, specialty pharmacy channels, or markets with strong excipient-labeling preferences.

The commercial advantage would depend on whether the product can maintain comparable tablet size, dissolution, and cost. Removing lactose alone is unlikely to create durable differentiation unless paired with a clinically relevant benefit.

Enhanced-solubility formulations

A reformulated dronedarone product could use an amorphous solid dispersion, nanocrystal, cyclodextrin complex, or lipid-based delivery system. These technologies could target:

• Reduced food dependence.
• More consistent exposure.
• Lower dose strength.
• Smaller tablets.
• Improved dissolution in patients with variable gastrointestinal conditions.

The development burden would be substantially higher than for a conventional generic. A new dosage form or altered exposure profile may require a 505(b)(2) pathway in the United States rather than a standard ANDA, depending on the scope of the change and the regulatory strategy.

Lower-dose or titration products

Multaq is marketed as a 400 mg tablet. A 200 mg strength could support titration, dose interruption, swallowing flexibility, or special-population use. The opportunity is clinically plausible but commercially constrained because the approved dosing regimen is 400 mg twice daily and any lower-dose positioning would require regulatory support.

A scored 400 mg tablet could provide some flexibility, but tablet scoring would require control of dose uniformity, breakability, stability, and label claims.

Combination and adherence products

Dronedarone could theoretically be combined with adherence-support products, calendar packaging, or co-packaged anticoagulant therapy. A fixed-dose combination would face substantial clinical and regulatory hurdles because anticoagulants have different dosing, contraindication, and monitoring requirements.

Co-packaging is more practical. A monthly adherence pack containing Multaq-equivalent tablets, dosing reminders, and medication reconciliation tools could support specialty-pharmacy and cardiology channels without changing the active formulation.

What patents protect Multaq's excipient formulation?

The commercial assessment must distinguish between active-ingredient patents, formulation patents, method-of-use patents, and regulatory exclusivity.

Protection category	Relevance to Multaq
Active-ingredient or chemical patents	May cover dronedarone or its salts and provide the earliest composition protection
Formulation patents	May cover excipient combinations, dissolution systems, particle properties, or dosage forms
Method-of-use patents	May cover treatment of atrial fibrillation or specific patient populations
Manufacturing patents	May cover crystallization, purification, particle engineering, or tablet manufacture
FDA regulatory exclusivity	Includes NCE, orphan, pediatric, or other statutory periods where applicable
Orange Book listings	Identify patents that the NDA holder submitted as relevant to approved use or product protection

The FDA approved Multaq on July 1, 2009 [2]. Dronedarone received new chemical entity exclusivity, which generally provided five years of U.S. exclusivity from approval, subject to applicable statutory rules. That period has expired. Patent and litigation status must be evaluated from current FDA Orange Book entries, USPTO records, and court dockets rather than inferred from the original approval date [3][4].

Because the commercial question concerns excipient strategy, the most relevant patent risks are formulation and manufacturing claims. A generic developer should screen claims covering:

• Poloxamer-containing oral compositions.
• Specific drug-to-excipient ratios.
• Particle-size or crystalline forms of dronedarone hydrochloride.
• Dissolution specifications.
• Film-coated tablet architecture.
• Processes for blending, granulation, compression, or coating.
• Use in patients with paroxysmal or persistent atrial fibrillation.

A formulation that uses the same broad excipient classes may still avoid a patent if the claims require narrower concentrations, process steps, or physical properties. Conversely, a different excipient can still infringe a claim drafted around the active's physical form or dissolution performance.

When does Multaq lose exclusivity and what generic entry risks exist?

The original NCE exclusivity period has ended. Current entry risk depends on remaining Orange Book patents, regulatory review, Paragraph IV certifications, litigation outcomes, settlements, and commercial decisions by ANDA sponsors.

Paragraph IV challenge considerations

A Paragraph IV applicant may assert that an Orange Book-listed patent is invalid, unenforceable, or not infringed. The NDA holder may file suit within the statutory period, potentially triggering a 30-month stay of ANDA approval under the Hatch-Waxman framework [5].

For Multaq, a generic applicant's key technical arguments could include:

• The proposed formulation does not practice the asserted excipient combination.
• The formulation uses a non-infringing surfactant or binder.
• The claimed process is not used.
• The relevant patent claims are invalid for anticipation or obviousness.
• The patent does not cover the proposed use or labeling.

The principal formulation risk is claim scope. A narrow patent focused on a specific ratio or process may be easier to design around than a broad claim covering any immediate-release dronedarone tablet with defined dissolution characteristics.

What is the FDA regulatory status and Orange Book position of Multaq?

Multaq remains an FDA-approved prescription drug marketed by Sanofi in the United States. The FDA label identifies the 400 mg tablet, the approved atrial-fibrillation indication, the twice-daily meal-related dosing instruction, contraindications, warnings, and inactive ingredients [1].

The Orange Book is the operative source for current listed patents, therapeutic equivalence codes, and approved product information [3]. A commercial diligence review should confirm:

• Current NDA holder and marketing status.
• Listed patents and expiration dates.
• Any pediatric exclusivity adjustment.
• Approved generic products.
• Therapeutic equivalence ratings.
• Withdrawal or discontinuation status.
• Any changes to labeling or product presentation.

A product may be technically substitutable yet commercially unattractive if reimbursement, supply reliability, or litigation exposure limits market access.

Which companies can compete with Multaq?

Competition exists at three levels.

Dronedarone generic manufacturers

Generic manufacturers compete primarily on price, supply reliability, wholesaler access, and therapeutic-equivalence status. The leading commercial advantages are low-cost manufacturing, validated dissolution performance, and the ability to launch without infringing active formulation claims.

Alternative antiarrhythmic drugs

Multaq competes clinically with amiodarone, sotalol, flecainide, propafenone, and other rhythm-control approaches. These products have different safety profiles, monitoring requirements, patient restrictions, and generic pricing.

Amiodarone is generally less expensive but has significant organ toxicity and monitoring burdens. Sotalol has renal and QT-related management requirements. Multaq's commercial position depends on patient selection, physician preference, hospitalization outcomes, and payer policy rather than excipient differentiation alone.

Non-drug rhythm-control strategies

Catheter ablation and rate-control therapy affect the addressable market. A commercial forecast should therefore model new prescriptions, treatment persistence, discontinuation, hospitalization reduction, and switching to ablation or alternative antiarrhythmics.

How large is the commercial opportunity?

The opportunity is primarily a generic erosion and lifecycle-management case rather than an originator-growth case. Revenue exposure is driven by:

• U.S. and European generic entry timing.
• Number of approved ANDAs.
• Price erosion after launch.
• Sanofi's ability to retain branded demand.
• Prescriber confidence in therapeutic equivalence.
• Specialty-pharmacy and hospital contracting.
• Supply continuity and shortages.
• Use of 400 mg twice-daily therapy over long treatment periods.

A conventional generic can compete on cost. A differentiated formulation must justify higher development and manufacturing costs through one of four measurable benefits: improved adherence, reduced food dependence, lower tablet burden, or a clinically meaningful tolerability or exposure advantage.

What manufacturing and excipient barriers affect Multaq products?

Manufacturing barriers are manageable but should not be treated as trivial. Critical controls include:

1. Uniform distribution of poloxamer 407 in the blend or granulate.
2. Control of lactose moisture and particle size.
3. Consistent crospovidone performance.
4. Lubrication time and magnesium-stearate level.
5. Tablet porosity and compression force.
6. Coating weight gain and film uniformity.
7. Dissolution after accelerated and long-term storage.
8. Supplier qualification for all functional excipients.

Poloxamer 407 may create supply-chain and quality-management considerations because different suppliers and grades can produce different powder-flow, melting, wetting, or dissolution behavior. A dual-source strategy should be supported by comparability data, not only by compendial compliance.

Packaging is another opportunity. A high-barrier blister or bottle system could protect dissolution performance and reduce moisture-related variability. Packaging changes are usually more commercially defensible when linked to stability data, adherence, or patient handling.

How strong is the Multaq patent estate?

The estate should be rated as moderate for a conventional generic and potentially stronger for specialized formulation or manufacturing variants. The active-ingredient exclusivity period is over, while residual risk depends on live listed patents and non-Orange-Book intellectual property.

Risk area	Commercial assessment
Basic immediate-release tablet	Moderate development risk
Excipient substitution	Usually manageable, subject to dissolution and bioequivalence
Poloxamer replacement	Technical risk from altered wetting and exposure
New solubility technology	Higher regulatory and patent risk
200 mg strength	Moderate clinical and regulatory risk
Modified-release product	High development and regulatory risk
Manufacturing process redesign	Depends on process-claim scope
Co-packaging and adherence systems	Lower formulation risk, limited exclusivity potential

Key Takeaways

• Multaq is a 400 mg immediate-release dronedarone hydrochloride tablet taken twice daily with meals.
• Its excipient system uses lactose, hypromellose, poloxamer 407, crospovidone, silica, magnesium stearate, and conventional film-coating materials.
• Poloxamer 407 is the principal formulation excipient from a solubility and wetting perspective.
• The most practical generic strategy is a reference-like immediate-release formulation with controlled dissolution and fed-state bioequivalence.
• Differentiated opportunities include lactose-free tablets, improved-solubility systems, lower-dose presentations, high-barrier packaging, and adherence-oriented co-packs.
• U.S. NCE exclusivity has expired. Current entry risk depends on live Orange Book patents, Paragraph IV activity, litigation, settlements, and approved generic competition.
• Excipient similarity alone does not determine infringement. Claim scope, concentration ranges, physical properties, process steps, and labeling must be assessed.
• A reformulated product with reduced food dependence or altered exposure would likely require a more complex regulatory pathway than a standard ANDA.

FAQs

Can poloxamer 407 be replaced in a generic Multaq tablet?

Yes, a developer may use another wetting or solubilizing excipient, but the replacement must preserve dissolution, stability, and bioequivalence performance. It may also alter the formulation's patent position.

Does Multaq contain lactose?

Yes. The FDA label identifies lactose monohydrate as an inactive ingredient in the tablet core [1].

Could a generic Multaq tablet be made without lactose?

Yes. Microcrystalline cellulose, mannitol, dibasic calcium phosphate, or composite excipients could replace lactose, subject to formulation, stability, dissolution, and regulatory requirements.

Is a modified-release version of dronedarone commercially attractive?

The opportunity is technically possible but carries high regulatory and clinical risk. A modified-release product would need to establish an appropriate exposure profile and could require a 505(b)(2) or other non-ANDA development strategy.

Does the Multaq label require administration with food because of the excipients?

The meal requirement is tied to dronedarone exposure and product pharmacokinetics, not solely to excipient selection. A new formulation that claims reduced food dependence would require dedicated pharmacokinetic and regulatory support.

References

1. U.S. Food and Drug Administration. (2023). Multaq (dronedarone hydrochloride) tablets, prescribing information. Sanofi-aventis U.S. LLC.

2. U.S. Food and Drug Administration. (2009, July 1). FDA approves Multaq to reduce hospitalization risk for atrial fibrillation. https://www.fda.gov

3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/

4. United States Patent and Trademark Office. (2024). Patent Center. https://patentcenter.uspto.gov/

5. U.S. Food and Drug Administration. (2024). Abbreviated new drug application approvals and patent certifications. https://www.fda.gov/drugs/abbreviated-new-drug-application-anda/istanda-and-paragraph-certifications